Relmada Therapeutics Stock Alpha and Beta Analysis
| RLMD Stock | USD 3.02 0.12 4.14% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Relmada Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Relmada Therapeutics over a specified time horizon. Remember, high Relmada Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Relmada Therapeutics' market risk premium analysis include:
Beta 0.97 | Alpha 0.18 | Risk 4 | Sharpe Ratio 0.0569 | Expected Return 0.23 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Relmada |
Relmada Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Relmada Therapeutics market risk premium is the additional return an investor will receive from holding Relmada Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Relmada Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Relmada Therapeutics' performance over market.| α | 0.18 | β | 0.97 |
Relmada Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Relmada Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Relmada Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Relmada Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Relmada Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Relmada Therapeutics shares will generate the highest return on investment. By understating and applying Relmada Therapeutics stock market price indicators, traders can identify Relmada Therapeutics position entry and exit signals to maximize returns.
Relmada Therapeutics Return and Market Media
The median price of Relmada Therapeutics for the period between Tue, Sep 3, 2024 and Mon, Dec 2, 2024 is 3.31 with a coefficient of variation of 10.36. The daily time series for the period is distributed with a sample standard deviation of 0.33, arithmetic mean of 3.22, and mean deviation of 0.28. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insiders Who Purchased US663.4k Of Relmada Therapeutics Stock May Not Have Expected 14 percent Tumble | 09/06/2024 |
2 | Acquisition by Kelly Paul Edward of 25000 shares of Relmada Therapeutics at 2.59 subject to Rule 16b-3 | 09/09/2024 |
3 | Acquisition by Shenouda Maged of 21118 shares of Relmada Therapeutics at 2.73 subject to Rule 16b-3 | 09/10/2024 |
4 | Acquisition by Shenouda Maged of 24120 shares of Relmada Therapeutics at 2.95 subject to Rule 16b-3 | 09/11/2024 |
5 | Insider Spends US395k Buying More Shares In Relmada Therapeutics | 09/13/2024 |
6 | Relmada stock jumps as Jefferies upgrades | 09/17/2024 |
7 | Disposition of tradable shares by Ogorman Cedric of Relmada Therapeutics subject to Rule 16b-3 | 10/16/2024 |
8 | Disposition of 13000 shares by Casamento Charles J of Relmada Therapeutics subject to Rule 16b-3 | 10/22/2024 |
9 | Acquisition by Schmidt Eric Thomas of 57042 shares of Relmada Therapeutics subject to Rule 16b-3 | 10/28/2024 |
10 | Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 | 11/04/2024 |
11 | Relmada Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Financial ... | 11/08/2024 |
12 | Relmada Therapeutics to Present at Jefferies London Healthcare Conference | 11/19/2024 |
13 | Acquisition by Ence Chuck of 14500 shares of Relmada Therapeutics at 3.8657 subject to Rule 16b-3 | 11/20/2024 |
About Relmada Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Relmada or other stocks. Alpha measures the amount that position in Relmada Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2019 | 2021 | 2023 | 2024 (projected) | Payables Turnover | 4.5E-4 | 1.12E-4 | 1.29E-4 | 1.23E-4 | Days Of Inventory On Hand | 87.9K | 3.3M | 3.0M | 3.1M |
Relmada Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Relmada Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Relmada Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Relmada Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Relmada Therapeutics. Please utilize our Beneish M Score to check the likelihood of Relmada Therapeutics' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Relmada Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Relmada Therapeutics Backtesting, Relmada Therapeutics Valuation, Relmada Therapeutics Correlation, Relmada Therapeutics Hype Analysis, Relmada Therapeutics Volatility, Relmada Therapeutics History and analyze Relmada Therapeutics Performance. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Relmada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.